Summary
=======

In patients suspected of having COVID-19, the initial chest CT showed high sensitivity, but low specificity.

Key Results
===========

1.  ■ The sensitivity, specificity, positive predictive value, and negative predictive value (with 95% confidence intervals) were 93% (85-97%), 53% (27-77%), 92% (83-96%), 42% (18-70%), respectively. Similar results were shown in both geographic regions studied.

2.  ■ There were no significant differences in the distribution of positive rates of tests in the two geographic regions between CT (P=0.423) and reverse transcription polymerase chain reaction testing (P=0.931).

Introduction {#s1}
============

In December 2019, a major outbreak of viral pneumonia caused by a new coronavirus started in Wuhan, China ([@r1]-[@r3]). The disease caused by this novel virus has been named Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO) ([@r4]). The disease has spread widely throughout China, followed by other countries worldwide, and it is now considered a pandemic ([@r5]-[@r9]). As the disease spread in the communities has increased, many of the infected persons may not have an obvious history of exposure ([@r10]). The rapid rate of spread confirms the highly infectious nature of the novel coronavirus, which is transmitted from person to person by means of droplets, direct contact, and inhaled air ([@r11]).

Given that early detection and isolation of COVID-19 cases could potentially decrease the spread rate, initial efforts focused on the use of chest CT in the forefront of diagnosis, in addition to reverse transcriptase polymerase chain reaction (RT-PCR) testing ([@r12]). Most common CT features of COVID-19 include multilobar ground-glass opacities with or without consolidation in the periphery of the lungs ([@r13]-[@r16]). Although early studies evaluating the clinical performance of chest CT obtained at initial presentation in the city of Wuhan, China showed high sensitivity ([@r17]), it is still questionable if chest CT should have any role in routine screening for COVID-19 in patients with suspected infection. Therefore, the purpose of the present study was to evaluate the performance of chest CT in patients under investigation for COVID-19 from two centers in the province of Henan, China, which is located near the center of this pandemic.

Methods {#s2}
=======

Patients and Data Collection
----------------------------

This analysis was retrospective and approved by the relevant institutional review boards. The need for written patient consent was waived. The authors reviewed the medical records from 103 patients who were considered under investigation for COVID-19 between January 21, 2020, and February 14, 2020, from two areas in Henan Province, China. The inclusion criteria of patient under investigation are summarized in [**Table 1**](#tbl1){ref-type="table"} ([@r4]). The following exclusion criteria was applied: ([@r1]) A person with a history of fever for more than 14 days, but without symptoms and signs for acute respiratory infection (ARI) or exposure history within 14 days. ([@r2]) A person with history of ARI for more than 14 days, but without exposure history. ([@r3]) A person with history of ARI within 14 days, but without exposure history, laboratory tests, or other examination providing sufficient evidence to exclude COVID-19 (e.g., other respiratory viruses including influenza A \[H1N1, H3N2, H7N9\], influenza B, respiratory syncytial virus, parainfluenza, adenovirus, Severe Acute Respiratory Syndrome \[SARS\] coronavirus \[SARS-CoV\], and Middle East Respiratory Syndrome \[MERS\]). All patients under investigation were kept in hospital for at least 2 weeks. RT-PCR tests performed on throat-swab, sputum, or alveolar lavage fluid specimens in all patients were used as the standard of reference in this study. RT-PCR testing was performed within 3 days after initial chest CT scanning. For those who showed initially negative RT-PCR results, repeat tests were done at intervals of 1-3 days. Up to 4 tests RT-PCR tests were performed in each patient.
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These patients were also divided into two subgroups based on the geographical distribution. **Subgroup 1** included 56 residents from Xinyang and Zhumadian districts (population estimated in 11.6 million inhabitants), which are located in the southernmost area of Henan Province, adjacent to the city of Wuhan. **Subgroup 2** included 47 residents from Anyang district (population estimated in 5.2 million inhabitants), which is located in the northernmost area of Henan Province, relatively distant from Wuhan.

CT Scanning and Image Analysis
------------------------------

Chest Computed tomography (CT) was performed in all patients at initial clinical presentation by using multi-slice CT systems (Philips Brilliance 16-detector CT and Philips Brilliance 128-detector iCT, Philips, Best, Netherlands; GE Lightspeed 16-detector CT, GE Healthcare, Waukesha, WI), without intravenous contrast, using standard clinical protocols. Parameters used included a peak x-ray tube voltage of 120 kV, automatic tube current modulation (145-300mAs) and a slice thickness of 2 to 3 mm without interslice gap. Studies were obtained in supine position during inspiratory pause (except in one elderly patient, who was unable to hold his breath). The images were reviewed by 3 radiologists with 8-15 years of experience in chest CT imaging, who were blinded to the laboratorial status (including the RT-PCR testing) of the patients, using a clinical Picture Archiving and Communication System (PACS) workstation. All diverging interpretations were resolved by discussion until a consensus was reached.

All CT images were assessed according to previous reports of radiologic findings in COVID-19 ([@r13]-[@r16]), using the Fleischner Society lexicon as reference ([@r22]). The distribution of the lung opacities was defined as peripheral if the involvement was limited to the outer one-third of the lungs and it was defined as central if the involvement was limited to the inner two thirds of the lungs. Lymphadenopathy was defined as the presence of hilar or mediastinal lymph nodes ≥ 10 mm in short-axis dimension.

Statistical analysis
--------------------

The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for diagnosing COVID-19 are reported with 95% confidence interval (95% CI), using RT-PCR as reference. The continuous demographic features and CT radiation dose were described as mean (SD). Pearson Chi-square analysis was used to test differences in CT performance and RT-PCR positivity prevalence between geographic regions. Statistical analysis was performed using SPSS 26.0 software (International Business Machine, IBM, Armonk, NY). The statistical significance level was set to 0.05.

Results {#s3}
=======

A total of 103 patients underwent chest CT and RT-PCR, including 48 males and 55 females, with mean age of 46 ([@r15]) years, ranging from 12 to 98 years. The mean computed tomography dose index (CTDI) and dose-length product (DLP) were 9.34 (4.13) mGy and 314.03 (152.86) mGy-cm, respectively. A total of 88/103 (85%) patients had confirmation of COVID-19, and the number of patients diagnosed on the first, second, third, or fourth RT-PCR were 37 (42%), 29 (33%), 14 (16%), 8 (9%), respectively.

A total of 82/88 (93%) COVID-19 cases had abnormalities on CT ([**Table 2**](#tbl2){ref-type="table"}), while 6/88 patients had a normal CT. In 23/82 (28%) patients CTs showed pure ground-glass opacities (GGO) ([**Figure 1**](#fig1){ref-type="fig"}), and in 58/ 82 (71%) patients CTs patients showed GGO mixed with consolidation ([**Figure 2**](#fig2){ref-type="fig"}). Only one (1/82) patient showed pure consolidation in the right lower lobe. In terms of distribution of the pulmonary opacities, in 63/82 (77%) patients the distribution of the lung opacities was peripheral, in 3/82 (4%) patients the distribution was central, and in 16/82 (20%) patients the distribution was both central and peripheral. ([**Figure 3**](#fig3a){ref-type="fig"}). Of 82 patients, 25 (31%) patients had unilateral opacities and 57 patients (70%) had bilateral opacities. In addition, opacities tended to involve multiple lobes (81%): in 14 of 82 (17%) patients the right upper lobe was affected; in 37 patients (45%) the right middle lobe was affected; in 58 patients (71%) the right lower lobe was affected; in 17 patients (21%) the left upper lobe was affected; in 41 patients (50%) the lingula was affected; and in 63 patients (77%) the left lower lobe was affected. Meanwhile, lymphadenopathy and pleural effusion were less common. Only one patient had a unilateral pleural effusion, which was accompanied by low serum protein, elevated serum creatinine, and a history of chronic pyelonephritis, suggesting renal etiology. None of those patients in this cohort showed lymphadenopathy.

The sensitivity, specificity, PPV, and NPV (with 95% CI) were 93% (85-97%), 53% (27-77%), 92% (83-96%), and 42% (18-70%) in the entire cohort, respectively ([**Table 3**](#tbl3){ref-type="table"}). Similar results were seen in both geographic subgroups. The sensitivity, specificity, PPV, and NPV in **Subgroup 1** were 92% (80-97%), 63% (26-90%), 93% (81-98%), and 56% (23-85%), while in in **Subgroup 2** they were 95% (81-99%), 43% (12-80%), 90% (76-97%), and 60% (17-93%), respectively. In addition, there were no significant differences in the distribution of normal and abnormal CT or RT-PCR positivity in the two geographic subgroups (respectively, *P*=0.423 and *P*=0.931) ([**Table 4**](#tbl4){ref-type="table"} and [**Table 5**](#tbl5){ref-type="table"}, respectively).
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![44-year-old woman with fever for three days, lymphocytopenia and a traveling history to Wuhan in January 2020.Axial chest CT image shows bilateral peripheral multi-focal ground-glass opacities (arrows).](ryct.2020200092.fig1){#fig1}

![57-year-old man, lifelong inhabitant of Wuhan, China, with fever for 4 days, shivers and dry cough. Axial chest CT image shows peripheral and central multi-focal ground-glass opacities with small foci consolidation (arrow).](ryct.2020200092.fig2){#fig2}

![45-year-old man, with an exposure history of working in Wuhan. Presenting with fever for 2 days, cough, and sore throat. (a) Coronal and (b) sagittal chest CT images show a focus of ground glass in the peripheral right lower lobe (black arrow) and a smaller focus of ground glass in the central right lower lobe (white arrow)](ryct.2020200092.fig3a){#fig3a}

![45-year-old man, with an exposure history of working in Wuhan. Presenting with fever for 2 days, cough, and sore throat. (a) Coronal and (b) sagittal chest CT images show a focus of ground glass in the peripheral right lower lobe (black arrow) and a smaller focus of ground glass in the central right lower lobe (white arrow)](ryct.2020200092.fig3b){#fig3b}
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Comparison of the CT scanning between the two subgroups
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Comparison of the RT-PCR between the two subgroups
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Discussion {#s4}
==========

In the present study, the sensitivity and specificity of chest CT in patients under investigation for COVID-19 was 93% and 53%, respectively, using the results of RT-PCR as the standard of reference, with no significant differences between two distinct regions in the Chinese province of Henan, one of which is geographically closer to the center of the disease outbreak in Wuhan. The sensitivity in this study is similar to a previous study (97%) reported by Ai et al, who focused on the subjects in Wuhan ([@r17])

Noticeably, the sensitivity of the first RT-PCR testing was only about 42% in our study, increasing to 75% on the second round of testing. In fact, this observation has been also seen in reports from other medical centers ([@r18],[@r19]). As a result, many experts in China had proposed CT as a screening tool for COVID-19. Although CT was initially included in the diagnostic criteria for COVID-19 in Hubei province on the 5^th^ edition of the Diagnosis and Treatment Program of the 2019 New Coronavirus Pneumonia issued by the National Health Commission of China, it was later removed on the 6^th^ edition ([@r20]). Our results suggest that chest CT may have a limited screening role for patients under investigation, as the NPV for COVID-19 was only modest in both geographic regions (i.e., 56% - 60%). Currently, the definite diagnosis of COVID-19 still relies on RT-PCR or fast genetic sequencing.

The specificity of CT findings for COVID-19 in our study was relatively low, even in patients specifically under investigation for the disease. In fact, GGO, consolidation, interlobular/intralobular septa thickening, crazy paving pattern, or other features on CT have been reported in several other non-infectious and infectious processes, such as SARS, common viral pneumonias, and other interstitial lung diseases ([@r21]). In our study, 15 patients under investigation for COVID-19, who showed findings on CT consistent with the disease, were found to have other diagnoses. Our observation is aligned with other reports. For instance, Ai et al. estimated a sensitivity of 28% for the initial CT in a large single-center study in the city of Wuhan with 1,014 patients. ([@r17]). Slight differences in specificity between the two studies could have occurred due to diverse demographic profile, inclusion criteria, or diagnostic criteria.

Remarkably, 6/88 RT-PCR-positive patients had a normal CT. Follow-up CTs obtained 2 to 3 days after the initial scan in these patients (not systematically studied here) became positive in 1/6 patient, while the other 5 patients remained negative during their hospitalization. These 5 patients presented with normal lymphocyte count and only minor symptoms.

In this study, we also noted that none of the patients had mediastinal or hilar lymphadenopathy. Those CT findings are aligned with the report by Chung et al. ([@r14]). This special CT features accompanied with the decrease number of peripheral blood lymphocytes may contribute to disclose the pathogenesis of COVID-19 infection. Huang, et al. reported that the virus of COVID-19 can consume lymphocytes, which may also be an important substrate for the rapid proliferation of the virus in early stages of the disease ([@r3]). We contemplate that this cytopathic effect on lymphocytes could be one of the causes for the lack of lymphadenopathy.

This study is not without limitations. First, CT readers were aware of the high suspicion level for COVID-19 in the population cohorts, which could have led to observer bias. Nevertheless, they were still blinded to the RT-PCR status of the patients. Second, the PPV and NPV could be affected by local prevalence of COVID-19 in our sample of patients under investigation. To balance the magnitude of such effects, we included patients from distinct geographic regions from our province, one closer and another distant from the center of the outbreak. Last, we used RT-PCR in different specimens as the standard of reference in our study. Although the sensitivity of RT-PCR has been reported vary significantly, such effects could have been balanced in our study by obtaining multiple sequential tests during hospital admission.

Conclusion {#s5}
==========

We conclude that: ([@r1]) although initial chest CT showed a high sensitivity for detecting COVID-19, the NPV observed in both geographic regions (56% and 60%) were too low for proposing this exam as a screening tool in patients under investigation; ([@r2]) The specificity of CT findings was also relatively low, reinforcing the need to consider all the clinical information, exposure history, and alternative diagnoses.

These authors contributed equally to this work.
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